Table 1.
Baseline Characteristics of the Cohort
| Total Cohort | Jan 2014–Nov 2014 | Nov 2014–Aug 2016 | Aug 2016–Jul 2018 | |
|---|---|---|---|---|
| No. of patients (%) | 668 (100.0) | 162 (24.3) | 256 (38.3) | 250 (37.4) |
| Sex, No. (%) | ||||
| Female | 301 (45.1) | 65 (40.1) | 122 (47.7) | 114 (45.6) |
| Male | 367 (54.9) | 97 (59.9) | 134 (52.3) | 136 (54.4) |
| Age, mean (range), y | 55.5 (18–85) [6.6% ≥75 y] | 55.3 (24–81) [3.1% ≥75 y] | 58.2 (24–85) [9.8% ≥75 y] | 52.9 (18–82) [5.6% ≥75 y] |
| Cirrhosis, No. (%) | 301 (45.1) | 130 (80.2) | 113 (44.1) | 58 (23.2) |
| Child A | 247 (82.1) | 108 (83.1) | 94 (83.2) | 45 (77.6) |
| Child B | 38 (12.6) | 19 (14.6) | 10 (8.8) | 9 (15.5) |
| Child C | 5 (1.7) | 2 (1.5) | 3 (2.7) | 0 (0) |
| N/A | 11 (3.7) | 1 (0.8) | 6 (5.3) | 4 (6.9) |
| HCV genotype, No. (%) | ||||
| 1 | 477 (71.4) | 101 (62.3) | 217 (84.8) | 159 (63.6) |
| 2 | 29 (4.3) | 13 (8.0) | 2 (0.8) | 14 (5.6) |
| 3 | 123 (18.4) | 42 (25.9) | 23 (9.0) | 58 (23.2) |
| 4 | 22 (3.3) | 4 (2.5) | 7 (2.7) | 11 (4.4) |
| 5 | 7 (1.0) | 1 (0.6) | 2 (0.8) | 4 (1.6) |
| 6 | 1 (0.1) | 0 (0) | 0 (0) | 1 (0.4) |
| N/A | 9 (1.3) | 1 (0.6) | 5 (2.0) | 3 (1.2) |
| No. outpatient medications, median (range) | 3 (0–19) | 3 (0–18) | 3 (0–16) | 2 (0–19) |
| Kidney transplant patients receiving sirolimus, everolimus, cyclosporine, or tacrolimus | 16 (2.4) | 0 (0) | 6 (2.3) | 10 (4.0) |
Abbreviations: HCV, hepatitis C virus; N/A, not available.